Astria Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update
Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today reported financial results for the first quarter ended March 31, 2024, and provided a corporate update.
- Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today reported financial results for the first quarter ended March 31, 2024, and provided a corporate update.
- The trial saw a 92-100% decrease in moderate or severe attacks and a 91-95% reduction in attacks requiring rescue medications with STAR-0215.
- Based on the positive results from the ALPHA-STAR trial, Astria plans to advance STAR-0215 to Phase 3 development.
- The 2023 report provides a comprehensive update on the Company’s performance and progress across key Environmental, Social, and Governance (ESG) areas of focus.